IgniteData and Memorial Sloan Kettering Cancer Center Announce Collaboration
IgniteData has announced a new collaboration with Memorial Sloan Kettering Cancer Center (MSK). Joining the MSK Innovation Hub, IgniteData will provide data transfer integration between the EHR at MSK and the electronic systems of two major clinical trial sponsors, with the expectation of expanding this project to include additional sponsors and trials. The collaboration is aiming to improve the process of data collection for cancer research by reducing the requirement for time-consuming data duplication and source data verification (SDV).
IgniteData’s system-agnostic electronic data transfer technology, Archer, eliminates the need for researchers to manually transcribe data such as vital signs and labs. Archer’s Smart Mapping Engine matches site and sponsor ontologies and normalises complex healthcare data. The solution enables research staff to transfer existing regulatory-grade data from the EHR to the sponsor’s study database.
The MSK Innovation Hub brings together health technology innovators and MSK’s community of researchers, clinicians, and digital health professionals through a program designed to advance the prevention, treatment, and cure of cancer. The MSK Innovation Hub is targeted at accelerating development of innovative products and businesses.
Reference
IgniteData and Leading New York City Cancer Center Collaborate to Solve the Clinical Trial Data Transfer Challenge. (2023, June). IgniteData.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
